Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.6, 2009-06, pp. : 1445-1454

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

ANNALS OF NEUROLOGY, Vol. 77, Iss. 3, 2015-03 ,pp. : 425-435

John Wiley & Sons Inc

Access to resources Recommend Favorite

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 22, Iss. 3, 2015-03 ,pp. : 570-577

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis

By de Sá J. Urbano G. Reis L.

Current Medical Research and Opinion, Vol. 26, Iss. 9, 2010-09 ,pp. : 2237-2242

Informa Healthcare

Access to resources Recommend Favorite

Teriflunomide for relapsing remitting multiple sclerosis

PRESCRIBER, Vol. 26, Iss. 18, 2015-09 ,pp. : 11-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

By Heeg B. M. S. Antunes J. Figueira M. L. Jara J. M. Marques Teixeira J. Palha A. P. Vaz Serra A. Buskens E. Caleo S. Gouveia-Pinto C. Van Hout B. A.

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 349-358

Informa Healthcare

Access to resources Recommend Favorite